Effects of broad-spectrum antibiotics on the colonisation of probiotic yeast \textit{Saccharomyces boulardii} in the murine gastrointestinal tract

Karl Alex Hedin, Vanessa Emily Rees, Hongbin Zhang, Vibeke Kruse, Ruben Vazquez-Uribe\textsuperscript{*} & Morten Otto Alexander Sommer\textsuperscript{*}

Mouse models are commonly used to study the colonisation profiles of microorganisms introduced to the gastrointestinal tract. Three commonly used mouse models include conventional, germ-free, and antibiotic-treated mice. However, colonisation resistance in conventional mice and specialised equipment for germ-free mice are usually limiting factors in their applications. In this study, we sought to establish a robust colonisation model for \textit{Saccharomyces boulardii}, a probiotic yeast that has caught attention in the field of probiotics and advanced microbiome therapeutics. We characterised the colonisation of \textit{S. boulardii} in conventional mice and mice treated with a cocktail of broad-spectrum antibiotics, including ampicillin, kanamycin, metronidazole and vancomycin. We found colonisation levels increased up to 10,000-fold in the antibiotic-treated mice compared to nonantibiotic-treated mice. Furthermore, \textit{S. boulardii} was detected continuously in more than 75% of mice for 10 days after the last administration in antibiotic-treated mice, in contrast to in nonantibiotic-treated mice where \textit{S. boulardii} was undetectable in less than 2 days. Finally, we demonstrated that this antibiotic cocktail can be used in two commonly used mouse strains, \textit{C57BL/6} and \textit{ob/ob} mice, both achieving ~10\textsuperscript{8} CFU/g of \textit{S. boulardii} in faeces. These findings highlight that the antibiotic cocktail used in this study is an advantageous tool to study \textit{S. boulardii} based probiotic and advanced microbiome therapeutics.

The human body hosts trillions of microorganisms, consisting of a diverse range of different communities of commensal, pathogenic and symbiotic microorganisms that together make up the human microbiota\textsuperscript{1,2}. These communities reside in numerous environmental sites on and within the human body, such as the skin, oral cavity, respiratory tract and gastrointestinal tract\textsuperscript{3}. The gastrointestinal tract contains the most abundant and diverse microbial communities in the human body\textsuperscript{2}. The attributes of these communities in the gastrointestinal tract play an essential role in sensing, responding and manipulating the human gut environment\textsuperscript{4}. Recent studies on the function of the human gut microbiota support it as a potential target to prevent numerous diseases, including diabetes, cancer, mental health, and obesity\textsuperscript{5–10} via probiotic administration or faecal matter transplants\textsuperscript{11–13}.

In addition, an emerging therapeutic modality involves engineered probiotic microorganisms to create advance microbial therapeutics (AMTs)\textsuperscript{14}. These engineered microorganisms may exhibit therapeutic activities in the gastrointestinal tract, skin, or blood of their hosts\textsuperscript{15–19}. Commonly used probiotic bacteria have been utilised as AMT chassis; for example, \textit{Lactococcus lactis} and \textit{Lactobacillus gasseri} have been engineered to prevent exacerbation of diabetes\textsuperscript{20–23}, and \textit{Escherichia coli} Nissle 1917 to treat phenylketonuria\textsuperscript{16} and hyperammonaemia\textsuperscript{17}. Bacteria offer some benefits as AMT chassis due to their simplicity of engineering and as they natively occur in high abundance in the gut\textsuperscript{1}. However, for the expression of peptides with post-translational modifications of proteins, eukaryotic hosts may be advantageous.

The probiotic yeast, \textit{Saccharomyces cerevisiae} var. \textit{boulardii}, a subspecies of the commonly used baker’s yeast, \textit{Saccharomyces cerevisiae}, has caught the attention within the field of probiotics and AMTs\textsuperscript{24–27}. \textit{S. boulardii} taken as a probiotic supplement has been reported to ameliorate certain antibiotic-associated disorders\textsuperscript{28}, such as \textit{Clostridium difficile} infections\textsuperscript{29,30}, inflammatory bowel disease\textsuperscript{31} and other gastrointestinal disorders\textsuperscript{29,32}.

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
\textsuperscript{*}email: ruvas@biosustain.dtu.dk; msom@bio.dtu.dk
Established genetic tools for *S. cerevisiae* can also be applied to *S. boulardii* as they are closely related, allowing *S. boulardii* to be used as an AMT chassis. Examples of this include engineering *S. boulardii* to secrete IL-10 to enhance its anti-inflammatory properties and to secrete atrial natriuretic peptide to treat murine colitis, thus demonstrating *S. boulardii* as a promising AMT platform, in addition to a probiotic itself.

Regrettably, *S. boulardii* has not been considered an efficient coloniser in conventional rodents with an intact microbiome due to its low abundance and short residence time in the gastrointestinal tract. For instance, in conventional mice *S. boulardii* was completely washed-out after two days, even though it can survive the low pH of the stomach and harsh conditions of the gastrointestinal tract. Conversely, *S. boulardii* administered to germ-free mice colonise the gastrointestinal tract for 30 days after a single administration. However, the cost and accessibility of such mouse model are limiting factors. Studying a disease that requires a stable delivery of the therapeutic would require more consistent *S. boulardii* levels. However, accessibility to a germ-free murine model and poor colonisation in conventional murine models complicates the preclinical assessment of the probiotic yeast. Considering the importance of robustness in preclinical assessment, a need remains for standardised colonisation and testing of *S. boulardii* in murine models. To address this problem, we sought to establish an antibiotic-treated model for *S. boulardii* to achieve reproducible and robust colonisation in mice.

**Results**

Pre-treatment with an antibiotic cocktail significantly extends *Saccharomyces boulardii* colonisation in mice. Use of an antibiotic-treated mice model for *S. boulardii* should reduce the potential variability in colonisation introduced with the environment, diet, breed, and other factors, which alter the gut microbiota. We hypothesised that treatment with a combination of broad-spectrum antibiotics would eliminate gut bacteria competing with *S. boulardii*, allowing for more robust colonisation and better reproducibility. We used an antibiotic cocktail containing ampicillin, kanamycin, metronidazole, and vancomycin enabling us to nate gut bacteria competing with *S. boulardii*, allowing for more robust colonisation and better reproducibility.

Antibiotic supplemented drinking water enhanced the colonisation of *S. boulardii* with 100% of the treated mice showing detectable colonisation of *S. boulardii* for the first six days, with 75% remaining with detectable levels for a prolonged period up to 10 days (Fig. 1b). In contrast to the nonantibiotic-treated mice that demonstrated complete washout of *S. boulardii* after a short period (up to 2 days). Additionally, we observed a more than a 1,000-fold increase of viable CFU/g in faeces during the period of daily oral administrations of *S. boulardii* for the antibiotic-treated mice compared to nonantibiotic-treated mice (Fig. 1c–d).

We further determined the colonisation of *S. boulardii* in different regions of the gastrointestinal tract. In all of the collected gut regions we observed a significant increase of viable *S. boulardii* CFU in the antibiotic-treated mice (Fig. 1c–f). Furthermore, *S. boulardii* was able to colonise all regions of the antibiotic-treated mice, while in the nonantibiotic-treated mice it was undetectable for most of the stomach and small intestine samples (Fig. 1f).

**Antibiotic cocktail opens a niche in the murine gastrointestinal tract for *S. boulardii* colonisation.** Once the residence time was assessed we sought to investigate the effect on the total bacterial communities in antibiotic-treated mice. The mice were orally administered ~ 10^7 cells of *S. boulardii* and faecal samples were collected daily until sacrifice on day five (Fig. 2a). Receiving an antibiotic cocktail reduced the total bacterial abundance by four orders of magnitude (Fig. 2b). Additionally, receiving the oral administration of ~ 10^8 *S. boulardii* cells together with the antibiotic cocktail resulted in an abundance three orders of magnitude greater than the nonantibiotic-treated mice (Fig. 2c).

**Receiving an antibiotic cocktail enables *Saccharomyces boulardii* to achieve reproducible and robust colonisation in two common mouse strains.** After establishing the residence time of *S. boulardii* following its administration and assessing the effect of antibiotics on the colonisation of *S. boulardii*, we sought to investigate the robustness with the antibiotic cocktail in two different mouse strains. We chose two of the most commonly used mouse models, the C57BL/6 fed with a high fat diet and the leptin deficient ob/ob mouse strain. The C57BL/6 mouse strain is used frequently in research including that for metabolic diseases, oncology, immunology and toxicology, whilst the ob/ob strain is commonly used for studying Type II diabetes and obesity. These colonisation studies were performed independently, with oral administration of probiotic *S. boulardii* from two different batches that were delivered daily for five weeks (Fig. 3a). Notably the abundance in faeces reached ~ 10^9 CFU/g in both murine strains and maintained at a high abundance (~ 10^9 CFU/g) throughout the five weeks (Fig. 3b–d).

**Discussion**

Since the early days of microbiome research, mouse models have been used to investigate how microbes interact with their hosts. In particular, germ-free and antibiotic-treated mice have been a valuable tool to study the direct interaction of a single or a defined community of microbes in the gastrointestinal tract. In this study, we characterised the effect of an antibiotic cocktail to build a robust mouse model for colonisation of *S. boulardii*. We started with orally administered ~ 10^7 cells (Fig. 1a) to correlate our observed colonisation with previous studies with *S. boulardii*. The oral administered *S. boulardii* was later increased by tenfold to boost to colonisation (Figs. 2a, 3a). Here we demonstrated that treating mice with a cocktail of antibiotics enabled *S. boulardii* to...
Figure 1. Colonisation assessment of *S. boulardii* in antibiotic-treated mice. (a) A graphical scheme of the study design. The mice were orally administered ~10^7 cells of *S. boulardii* daily for five successive days, followed by a 15-day washout period (grey shaded area). The mice were divided into two cohorts, where one received antibiotics supplemented in the drinking water. On the fifth day, half of the mice were sacrificed to determine the colonisation of *S. boulardii* in different gut regions. (b) The step plot shows the time-course of percentage of mice with detectable levels of *S. boulardii* in the antibiotic-treated cohort (blue) and the none-antibiotic-treated cohort (red). (c) The time-course of the log_{10} mean CFU/g of *S. boulardii* ± SEM mean over time (days) in faeces. Each dot represents the log_{10} CFU/g *S. boulardii* in one mouse. (d) Bar plot of the mean CFU/g of *S. boulardii* assessed in the faeces over the first five days. (e) A graphical illustration of the different gut regions investigated and how the regions were defined as marked. (f) Box plot of the assessed CFU/g of *S. boulardii* in the gastrointestinal tract from the nonantibiotic-treated and antibiotic-treated mice sacrificed on the fifth day. *p < 0.5, **p < 0.1, ***p < 0.01, ****p < 0.001. All samples were analysed by a dependent sample t-test.
remain in 75% of mice for 10 days and 25% of mice for 15 days (Fig. 1b) following the last oral administration. This was in stark contrast to the colonisation observed in the nonantibiotic-treated mice that demonstrated complete washout of \textit{S. boulardii} after two days. This latter observation appears identical to a previous study that compared \textit{S. boulardii} in mice treated with a cocktail of penicillin (1 mg/mL) and streptomycin (2 mg/mL), where \textit{S. boulardii} still appeared to washout after two days\textsuperscript{26}. This emphasised the importance of the use of the broad-spectrum antibiotic cocktail in this study. In addition, we observed more than a 1,000-fold increase in viable count of \textit{S. boulardii} in faeces from antibiotic-treated mice compared to nonantibiotic-treated mice (Figs. 1d, 2c).

The gut microbiota of mice from the same breed has previously been shown to differ significantly between suppliers resulting in challenges to reproduce experiments\textsuperscript{50–52}. In this study, we demonstrated the robustness of the antibiotic cocktail model, showing an insignificant difference in colonisation for the first four weeks between two different studies (Fig. 3b–d). We showed that the antibiotic cocktail in mice exhibits reproducible colonisation of \textit{S. boulardii} in two different mouse strains (C57BL/6 and \textit{ob/ob}) under two different diets (standard chow and high fat diet). These studies were conducted independently with two different batches of \textit{S. boulardii}, maintaining ~ 10\textsuperscript{8} CFU/g in faeces for up to five weeks (Fig. 3b). Interestingly, here we observed ~ tenfold higher CFU/g counts in faeces of antibiotic-treated mice compared to previously reported numbers in germ-free mice\textsuperscript{26}.

Comparing the viable counts in the different regions, we observed a significant increase in all regions by supplementing antibiotics in the drinking water, highlighting the potential of \textit{S. boulardii} to act on multiple sections of the gastrointestinal tract (Fig. 1f). We observed the largest increase in viable cells in the jejunum and stomach, which increased by ~ 10,000-fold when antibiotics were supplemented. This was followed by the ileum and lower intestinal tract, which all increased by ~ 1,000-fold viable cells. Furthermore, the ability of \textit{S. boulardii} to colonise the antibiotic-treated mice were 10- to 100-fold lower than some of the more common bacterial probiotics\textsuperscript{53,54}, such as \textit{E. coli} Nissle 1917 which can reach up to 10\textsuperscript{9} cells/g in faeces\textsuperscript{55}.

Treating mice with broad-spectrum antibiotics has been commonly used to deplete bacterial populations in the gastrointestinal tract. We used a cocktail of antibiotics that has previously been demonstrated to open a niche in the gastrointestinal tract\textsuperscript{44–46}. In our study, using this antibiotic cocktail showed no growth burden for \textit{S. boulardii} (Supplementary Fig. S1). Distinctly, the antibiotic cocktail of this study significantly impacted the total bacterial abundance, as observed by a 10,000-fold decrease of bacterial cells (Fig. 2b). Although the treatment
cannot completely eliminate the gut microbiota, it represents a rapid, inexpensive and accessible alternative to the germ-free model. Further studies would be necessary to fully elucidate the long-term colonisation effects and dynamics of *S. boulardii* as well as other fungal species on the host. Indeed, it has been demonstrated that antibiotics have a long-term effect on the fungal community in the gut, shifting from mutualism towards competition. To reduce the risk of other fungal species taking over or competing with *S. boulardii*, anti-fungal compounds that *S. boulardii* has been engineered to resist could be added to the antibiotic cocktail.

Investigation of physiological effects of *S. boulardii* based probiotics and AMTs requires animal models that allow robust and consistent colonisation. In this study, we demonstrated that treatment with an antibiotic cocktail led to reproducible and robust colonisation of *S. boulardii* throughout the gastrointestinal tract. This model may be useful as a rapid, low-cost setup for testing *S. boulardii* AMTs and probiotics.

**Methods**

**Strains and media.** One Shot® TOP10 *Escherichia coli* (Thermo Fisher Scientific, Waltham, MA, USA) were used for plasmid construction and maintenance. *E. coli* cultures were grown in lysogeny broth (LB) media containing 5 g/L yeast extract, 10 g/L tryptone and 10 g/L NaCl (Sigma Aldrich—Merck Life Science) supplemented with 100 mg/L ampicillin sodium salt (Sigma Aldrich—Merck Life Science). *S. boulardii* (*S. cerevisiae* ATCC® MYA796) was obtained from American Type Culture Collection, ATCC. The strains created in this study are listed in Supplementary Table S2. *S. boulardii* were cultured in yeast extract peptone dextrose (YPD) media containing 10 g/L yeast extract, 20 g/L casein peptone and 20 g/L glucose; (Sigma Aldrich—Merck Life Science) at 37 °C. Strain selection was done on YPD plates containing 20 g/L agar and supplemented with 200 mg/L gentamicin (G418; Sigma Aldrich—Merck Life Science) or synthetic complete (SC) plates containing 1.7 g/L yeast nitrogen base without amino acids and ammonium sulphate (Sigma Aldrich—Merck Life Science), 1 g/L monosodium glutamate (Sigma Aldrich—Merck Life Science), 1.92 g/L Yeast Synthetic Drop-out Medium Supplements without uracil (Sigma Aldrich—Merck Life Science) and 0.2 g/L uracil (Sigma Aldrich—Merck Life Science) at 37 °C.
Strain and plasmid construction. The oligonucleotides and gBlock sequences were codon-optimised and ordered from Integrated DNA Technologies (IDT; sequences are listed in Supplementary Information Table S1). All plasmids used and generated in this study are listed in Supplementary Information Table S3. Phusion high-fidelity DNA polymerase (Thermo Scientific, Waltham, MA, USA) was used for amplifying GFP. GFP was assembled with the integration plasmid pCIB2055 using Gibson Assembly and digested with NotI prior to integration. Colony-PCR using OneTaq (Thermo Scientific, Waltham, MA, USA) was used for confirming the integration of pCIB2055. GFP. Primers flanking the integration was used to confirm the integration. One single amplification band on gel electrophoresis indicated a successful integration into both chromosome copies. Genomic DNA extraction was performed as described previously.

To generate the uracil knockout strain, the gBlock with URA3 gRNA was assembled with pCIB2312 (Cas9-KanMX) to build the pCIB2312_URA and transformed together with URA-donor-fw primer (TTCAATGGAG GGCACAGTTAAGCGCCTAAGAACAGTACAAATTTTTAATCT) and URA-donor-rv primer (ACCAGTTCGAAATTTAGCTTTGAGATTTAATGTC). S. boulardii transformations were performed via high-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method with a minor modification of the incubation and heat-shock temperatures of 37 and 45 °C were used, respectively.

Real-time growth monitoring. Real-time OD600 measurements were obtained every 5 min for approximately 24 h with microplate reader Synergy H1 BioTek. The cultures were incubated into 200 µL YPD in a CELLSTAR* 96 well cell culture plate (Greiner Bio-One) with an air-penetrable lid (Breathe-Easy, Diversified Biotech) supplemented with 0.3 g/L ampicillin sodium salt, 0.3 g/L kanamycin sulfa (Sigma Aldrich—Merck Life Science), 0.3 g/L metronidazole (Sigma Aldrich) and 0.15 g/L vancomycin hydrochloride (MP Biomedicals, LLC). Cultivation was performed with continuous double orbital shaking of 548 cycles per minute (CPM) at 37 °C and with an initial OD600 of 0.10.

Animal study. All animal experiments were conducted according to the Danish guidelines for experimental animal welfare and the study protocols were approved by the Danish Animal Experiment Inspectorate (license number 2020-15-0201-00405). The study was carried out in accordance with the ARRIVE guidelines. Unless otherwise stated, all mice were housed on a 12-h light/dark cycle and given ad libitum access to standard chow (Safe Diets, A30) and water. For the high fat diet studies, 45% high fat diet (Research Diet, D12451 Rodent Diet) was used. The NRMI mice were divided into two cohorts (n = 16), with and one without antibiotic-treatment. Both cohorts were orally administered via intragastric gavage with ~10⁸ CFU of S. boulardii in 100 µL of 1× PBS and 10% glycerol and weighed to determine the faecal weight. All sample preparation for assessing CFU numbers was kept at 4 °C and followed the same practice. The faecal samples...
were homogenised and vortexed at ~2400 rpm for 10 min. The samples were then spun down at 100 g for 30 s, followed by a dilution series, where 5 µL of each dilution was plated in duplicates or triplicates. The faecal samples were plated on YPD plates containing 200 mg/L G418 for selecting the S. boulardii the faecal samples were plated on SC plates containing 100 mg/L ampicillin, 50 mg/L kanamycin, and 30 mg/L chloramphenicol (Sigma Aldrich—Merck Life Science) for preventing bacterial growth and 1 g/L 5-Fluoroorotic Acid (5-FOA; Nordic BioSite) for preventing other yeast species to grow. To lower the limit of detection, 100 µL of the faecal samples was plated in duplicates from day 10 (Fig. 1b).

**Real-time quantitative PCR.** According to the manufacturer’s instructions, all genomic DNA were extracted with the DNeasey PowerSoil Pro kit (Qiagen, Hilden, Germany). The DNA concentration was determined with Qubit (Qubit™ dsDNA HS Assay Kit, Thermo Scientific, Waltham, MA, USA). 2 x SensiFAST SYBR® Lo-ROX mix (Nordic BioSite) was used for all qPCR reactions, consisting of 5 µL of master mix, 0.03 µL of each primer (100 µM, see Supplementary Table 1) and 5 µL of 0.1 ng/L of extracted template DNA. All qPCR reactions followed the same thermocycler program that consisted of an initial 3 min step at 95 °C, followed by 40 cycles of 95 °C for 10 s, 60 °C for 15 s, and 72 °C for 30 s, along with a final melting curve consisting of a single cycle of 95 °C for 5 s, 60 °C for 1 min, 95 °C for 5 s. All samples were run in duplicate.

Bacterial cell counts were determined using 16S rRNA and GFP specific primers for the total bacteria and S. boulardii cell counts, respectively (Supplemented Table S1). Cell counts were calculated based on a standard curve generated using a series of OD from either E. coli or S. boulardii and yielded genomic DNA concentration. We adjusted the qPCR signal of 16S and GFP by dividing them by the mean copy numbers per genome63; this was done to account for the fact that the 16S and GFP copy numbers per genome vary between species63–65, which consequently skew the readout of bacterial and S. boulardii cell counts. qPCR runs were performed on the Roche LightCycler® 480 Real-time PCR System in LightCycler® 480 Multiwell Plate 384, clear plates.

**Statistical testing.** All statistical analysing were performed in RStudio. The normality of the data was checked with the Shapiro–Wilk test. A dependent sample t-test was used for normally distributed data and the Wilcoxon singed-rank test for non-normal distributed data. P values <0.05 were considered statistically significant.

**Data availability**

All data generated or analysed during this study are included in this published article and its Supplementary Information files.

Received: 14 January 2022; Accepted: 19 April 2022
Published online: 25 May 2022

**References**

1. Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol.* **14**, e1002533 (2016).
2. Huttenhower, C. et al. Structure, function and diversity of the healthy human microbiome. *Nature* **486**(7402), 207–214 (2012).
3. Ma, Z., Li, L. & Li, W. Assessing and interpreting the within-body biogeography of human microbiome diversity. *Front. Microbiol.* **9**, 1619 (2018).
4. Kolde, R. et al. Host genetic variation and its microbiome interactions within the Human Microbiome Project. *Genome Med.* **10**, 1–13 (2018).
5. Guinane, C. M. & Cotter, P. D. Role of the gut microbiota in health and chronic gastrointestinal disease: Understanding a hidden metabolic organ. *Ther. Adv. Gastroenterol.* **6**, 295–308 (2013).
6. Muscogiuri, G. et al. Gut microbiota: a new path to treat obesity. *Int. J. Obes. Suppl.* **9**(1), 10–19 (2019).
7. Das, T. et al. Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy. *Sci. Rep.* **11**, 2738 (123AD).
8. Heshiki, Y. et al. Predictable modulation of cancer treatment outcomes by the gut microbiota. *Microbiome* **8**, 1–14 (2020).
9. Xavier, J. R. et al. The cancer microbiome: distinguishing direct and indirect effects requires a systemic view. *Trends Cancer* **6**, 192–204 (2020).
10. Schächtle, M. A. & Rosshart, S. P. The microbiota-gut-brain axis in health and disease and its implications for translational research. *Front. Cell. Neurosci.* **9**, 1–14 (2015).
11. Liu, Y., Tran, D. Q. & Rhoads, J. M. Probiotics in disease prevention and treatment. *J. Clin. Pharmacol.* **58**, S164–S179 (2018).
12. Costello, S. P. et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. *Aliment. Pharmacol. Ther.* **46**, 213–224 (2017).
13. Barberio, B. et al. Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. *Ther. Adv. Gastroenterol.* **13**, 175628420934315 (2020).
14. O’Toole, P. W., Marchesi, J. R. & Hill, C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. *Nat. Microbiol.* **2**(5), 1–6 (2017).
15. Mimeo, M., Citorik, R. J. & Lu, T. K. Microbiome therapeutics—advances and challenges. *Adv. Drug Deliv. Rev.* **105**, 44–54 (2016).
16. Isabella, V. M. et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. *Nat. Biotechnol.* **36**(9), 857–864 (2018).
17. Kurtz, C. B. et al. An engineered *E. Coli* Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. *Sci. Transl. Med.* **11**, 7975 (2019).
18. May-Zhang, L. S. et al. Administration of N-Acyl-Phosphatidylethanolamine expressing bacteria to low density lipoprotein receptor−/− mice improves indices of cardiometabolic disease. *Sci. Rep.* **9**(1), 1–13 (2019).
19. Pedrolli, D. B. et al. Engineering microbial living therapeutics: the synthetic biology toolbox. *Trends Biotechnol.* **37**, 100–115 (2019).
20. Agarwal, P., Khatri, P., Billack, B., Low, W. K. & Shao, J. Oral delivery of Glucagon like peptide-1 by a recombinant *Lactococcus lactis*. *Pharm. Res.* **31**, 3404–3414 (2014).
21. Robert, S. et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63, 2876–2887 (2014).
22. Takishii, T. et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Investig. 122, 1717 (2012).
23. Duan, F. F., Liu, J. H. & March, J. C. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64, 1794–1803 (2015).
24. Bagherpour, G. et al. Oral administration of recombinant Saccharomyces boulardii expressing ovalbumin-CPE fusion protein induces antibody response in mice. Front. Microbiol. 9, 723 (2018).
25. Liu, C. H., Chang, J. H., Chang, Y. C. & Mou, K. Y. Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide. J. Mol. Med. (Berl) 98, 1675–1687 (2020).
26. Durmusoglu, D. et al. In situ biomanufacturing of small molecules in the Mammalian gut by probiotic Saccharomyces boulardii. ACS Synth. Biol. 10, 1039–1052 (2021).
27. Everard, A., Matamoros, S., Geurts, L., Delzenne, N. M. & Cani, P. D. Saccharomyces boulardii Administration Changes Gut Microbiota and Reduces Hepatic Steatosis, Low-Grade Inflammation, and Fat Mass in Obese and Type 2 Diabetic db/db Mice. mBio 5(3), e01101–14 (2014).
28. McFarland, L. V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. WJG 16, 2202 (2010).
29. Pothoulakis, C. et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104, 1108–1115 (1993).
30. Castagliuolo, I., Thomas Lamon, J., Nikulasson, S. T. & Pothoulakis, C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect. Immun. 64, 5225 (1996).
31. Dalmasso, G. et al. Saccharomyces boulardii Inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131, 1812–1825 (2006).
32. Keisidis, T. & Pothoulakis, C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther. Adv. Gastroenterol. 5, 111 (2012).
33. Hudson, L. E. et al. Functional Heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii. PLoS ONE 9, e112660 (2014).
34. Liu, J. J. et al. Metabolic engineering of probiotic Saccharomyces boulardii. Appl. Environ. Microbiol. 82, 2280 (2016).
35. Khatri, I., Tomar, R., Ganesan, K., Prasad, G. S. & Subramanian, S. Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii. Sci. Rep. 7(1), 1–12 (2017).
36. Hudson, L. E. et al. Characterization of the probiotic yeast Saccharomyces boulardii in the healthy mucosal immune system. PLoS ONE 11, e0153351 (2016).
37. Michael, S. et al. Quantitative phenotyping of inflammatory bowel disease in the IL-10-deficient mouse by use of noninvasive magnetic resonance imaging. Inflamm. Bowel Dis. 19, 185–193 (2013).
38. Liu, C. H., Chang, J. H., Chang, Y. C. & Mou, K. Y. Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide. J. Mol. Med. 98, 1675–1687 (2020).
39. Blehaut, H., Massot, J., Elmer, G. W. & Levy, R. H. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm. Drug Dispos. 10, 353–364 (1989).
40. Chen, K. et al. A probiotic yeast-based immunotherapy against Clostridiodes difficile infection. Sci. Transl. Med. 12, 567 (2020).
41. Fietto, J. L. et al. Molecular and physiological differences between Saccharomyces cerevisiae and Saccharomyces boulardii. Can. J. Microbiol. 50, 615–621 (2011).
42. Edwards-Ingram, L. et al. Genotypic and physiological characterization of saccharomyces cerevisiae, the probiotic Strain of Saccharomyces cerevisiae. Appl. Environ. Microbiol. 73, 2458 (2007).
43. Franklin, C. L. & Ericsson, A. C. Microbiota and reproducibility of rodent models. Lab. Anim. NY 46, 114 (2017).
44. Tirelle, P. et al. Comparison of different modes of antibiotic delivery on gut microbiota depletion efficiency and body composition in mouse. BMC Microbiol. 20, 1–10 (2020).
45. Kennedy, E. A., King, K. Y. & Baldridge, M. T. Mouse microbiota models: comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria. Front. Physiol. 9, 1534 (2018).
46. Levy, M. et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163, 1428–1443 (2015).
47. Song, H. K. & Hwang, D. Y. Use of C57BL/6N mice on the variety of immunological researches. Lab. Anim. Res. 33, 119 (2017).
48. Ingalls, A. M., Dickie, M. M. & Snell, G. D. Obese, a new mutation in the house mouse* . J. Hered. 41, 317–318 (1950).
49. Suleiman, J. B., Mohamed, M. & Bakar, A. B. A. A systematic review on different models of inducing obesity in animals: advantages and susceptibility to enteric salmonella infection. Infect. Immun. 77, 2741 (2009).
50. Long, L. L. et al. Shared and distinctive features of the gut microbiome of C57BL/6 mice from different vendors and production sites, and in response to a new vivarium. Lab Anim. 50(7), 185–195 (2021).
51. Kozakova, H. et al. Colonization of germ-free mice with a mixture of three lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell. Mol. Immunol. 13(2), 251–262 (2015).
52. Conway, T., Krogfelt, K. A. & Cohen, P. S. The life of commensal Escherichia coli in the mammalian intestine. Ecosal Plus 1(1). https://doi.org/10.1128/ecosalplus.8.3.1.2 (2004).
53. Gietz, R. D. & Woods, R. A. Yeast transformation by the LiAc/SS carrier DNA/PEG method. Methods Mol. Biol. 313, 107–120 (2006).
54. Amend, A. S., Seifert, K. A. & Bruns, T. D. Quantifying microbial communities with 454 pyrosequencing: does read abundance count? . Mol. Ecol. 19, 5555–5565 (2010).
65. Baldrian, P. et al. Estimation of fungal biomass in forest litter and soil. Fungal Ecol. 6, 1–11 (2013).

Acknowledgements
This work received funding from The Novo Nordisk Foundation under NNF grant number: NNF20CC0035580, NNF Challenge programme CAMiT under Grant agreement: NNF17CO0028232 and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant agreement No 813781. We are grateful to Kira Sarup-Lytzen, Felipe Gonzalo Tueros Farfan, Susanne Kammler and Max van ’t Hof for assistance in carrying out some of the experiments. We are also grateful to Kira Sarup-Lytzen and Mareike Bongers for initial discussions in the experimental setup.

Author contributions
K.A.H., R.V.U., V.E.R., and M.O.A.S. conceived the study, and all authors contributed to the study's design. K.A.H. carried out all in vitro characterisations, and K.A.H., V.K., V.E.R., and H.Z. carried out all the in vivo characterisations. K.A.H. analysed the data and wrote the manuscript. R.V.U., V.E.R., and M.O.A.S. supervised the study. All authors contributed to the discussion of the results. All authors read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-12806-0.

Correspondence and requests for materials should be addressed to R.V.-U. or M.O.A.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022